Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Amy Smithline

Gastroenterology Stamford, CT Medical Doctor

NPI 1538234240 CMS profile 251400

32 Strawberry Hill Ct, Ste 41042, Stamford, CT 06902

Open in the dashboard

General payments

$6,688

357 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Amy Smithline of Stamford, CT is reported in the CMS Open Payments database as having received $6,688 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $438 22
2021 General $2,209 120
2020 General $1,807 100
2019 General $2,235 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Smithline
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Amy Smithline were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Amy Smithline Gastroenterology median Middle half National median
2019 $2,235 $417 $126–$1,100 $163
2020 $1,807 $224 $74–$624 $114
2021 $2,209 $352 $106–$1,054 $132
2022 $438 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Salix Pharmaceuticals, a division of Bausch Health US, LLC $2,194 123 payments
  2. AbbVie, Inc. $892 48 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $572 24 payments
  4. Pfizer Inc. $557 30 payments
  5. Gilead Sciences, Inc. $484 33 payments
  6. Janssen Biotech, Inc. $360 20 payments
  7. RedHill Biopharma Inc. $308 14 payments
  8. Ethicon US, LLC $240 2 payments
  9. Ironwood Pharmaceuticals, Inc $178 11 payments
  10. Allergan Inc. $145 10 payments
  11. Other $758 42 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $6,688 357 payments
Products named General payments · program years 2019–2022
  1. XIFAXAN $1,878 103 payments
  2. XELJANZ $525 28 payments
  3. HUMIRA $432 23 payments
  4. CREON $422 23 payments
  5. STELARA $360 20 payments
  6. PLENVU $350 19 payments
  7. UCERIS $326 18 payments
  8. Talicia $308 14 payments
  9. MOTEGRITY $278 7 payments
  10. LINX Reflux Management System $240 2 payments
  11. Other $2,323 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$10,747

Medicare's payments for the services billed

Medicare patients

50

Average age 81

Services billed

115

30 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Ischemic heart disease 64%
Heart failure 56%
Chronic kidney disease 50%
Atrial fibrillation 48%
Arthritis 44%
Depression 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record